Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Objectives - The partnership will create synergies by combining MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Implications - This partnership signifies a significant transformation for the company, moving from early detection to prevention and precision medicine [1] - The collaboration is expected to create synergies by combining the company's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] Group 3: Operational Capabilities - The partnership will utilize the company's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1] - The collaboration will also enhance distribution channels within ASEAN, integrating research and commercial deployment into a cohesive prevention and precision medicine platform [1]

Core Insights - The company has signed a memorandum of understanding with Yunnan Watson Bio-Technology Co., Ltd. to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform [1][2] - The memorandum outlines a two-year collaboration period and includes joint development, clinical trials, registration, and sales and distribution [1] Group 1 - The partnership aims to leverage complementary strengths to enhance the company's position in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - The collaboration will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform is expected to facilitate cross-border investment opportunities, enhance corporate visibility, and deepen research and development capabilities [2] Group 2 - The partnership will establish an RNA-focused research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology [1] - Clinical trials and regulatory approvals for existing and pipeline products will be expedited in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve ASEAN and specific international markets [1]